COVID-19 Featured Question
Do I need to inform Advarra that my study was placed on hold due to COVID-19?
Read the answer | Ask the experts
Press Release
IRB Services
IBC Services
GxP/HRP Consulting Services
Canadian Review
Trust Advarra’s integrated solutions and collaborative approach to make your research altogether better.
Advarra® provides institutional review board (IRB), institutional biosafety committee (IBC) and GxP/HRP research compliance consulting services with unprecedented clarity.
Advarra recently acquired Forte, the market-leading provider of clinical technology solutions including OnCore. Learn more
Our Latest Updates
Discover What’s Happening at Advarra
ACRP Acknowledges Advarra for Its Free Resources During the COVID-19 Pandemic
ACRP recognized Advarra for the organization’s leadership and free guidance during the global COVID-19 pandemic in the blog article Clinical...
Ask Advarra Live: The Real-World Impact of COVID-19 on Research
The unprecedented COVID-19 pandemic has quickly changed how we live and work. This extraordinary situation has resulted in a significant impact on IRB-approved protocols and research yet to go through…
IRB Review of Coronavirus and Other Emerging Infectious Disease Research: Issues to Consider
In this blog we discuss unique issues that research involving emerging infectious diseases like coronavirus can raise for IRB review and research informed consent.
Are “Virtual Trials” Mainstream Yet?
While some completely virtual trials are taking place, the real trend involves bringing virtual trial components to traditional study designs to improve study efficiency and reduce participant burden.